GermanyGermany

IP Flash

04.11.2010

Steven M. Zeman, Ph.D., Dr. Franz-Josef Zimmer, European Patent Attorneys at Grünecker Patent- und Rechtsanwälte, Munich

On April 1, 2010 new rules for divisional applications came into force in the EPO. In the past one could file a “divisional” at any time during an application’s pendency. The new rules set limits on when and why divisionals may be filed. Applicants of older applications for which the new deadlines had already expired were given a final grace period to file all “voluntary” divisionals (more on these below…). This grace period ended on October 1, 2010 and triggered a flood of new divisionals in the EPO. With this flood just past, when and why may European divisionals now be filed?
As in the past, in order to be admissible, the divisional’s parent must still be pending when the divisional is filed. When an application is granted, it remains pending up to (but not in­cluding) publication of the grant. When an application is refused, it remains pending throughout the following

appeal period, even if no appeal is filed.
The old law knew only one type of divisional, but the new rules distinguish two types : voluntary and mandatory divisionals. “Voluntary” divisionals may be filed for any reason; “mandatory“ divisionals may only be filed in response to a unity objection. All voluntary divisionals must be filed within 24 months of the first communication of the EPO Examining Division (ED) in any earlier family member. Mandatory divisionals must be filed within 24 months of the ED’s communication in which it first raises a particular unity objection. Different unity objections trigger separate 24-month time limits when the objections are raised at different times.
In most cases, the “Communication of the Examining Division“ mentioned in the new rules will normally be an examination report under Art. 94(3) EPC. EPO search reports will not trigger time limits for divisionals (search reports are not prepared by the ED). Nor will an action issued by the EPO acting as a search or examination authority for an international (PCT) application.
To prevent loss of subject matter, applicants should note the 24 month time period from the first ED communication (time limit for filing voluntary divisionals). One should also carefully check each communication from the ED for any new unity objections, noting a separate 24 month time limit for each objection and requesting written clarification if necessary. The EPO’s “10-day-rule” for fictional notification of documents applies for the calculation of the 24 month time limits. Keeping careful track of these dates should help avoid loss of subject matter as a result of the EPO’s new legislation.

GermanyGermany

07.03.2012

The first of February marked a milestone for Leverkusen-based Bio­frontera AG in more ways than one. It was the first day that Ameluz, the firm’s first approved product, could be sold in German pharmacies. It was also the date...

GermanyGermany

07.03.2012

Darmstadt – German pharmaceutical and chemical company Merck KGaA has set a downbeat tone for 2012. CEO Karl-Ludwig Kley said the recently launched cost-cutting programme and tough economic conditions will weigh on profits this...

GermanyGermany

05.03.2012

Mainz/Leuna – Two biotech concepts were amongst the winners of the recent third round of the Excellence Cluster initiative, which is funded by the German Ministry for Research. In Mainz the champagne corks popped especially loud...

GermanyGermany

05.03.2012

German Merck KGaA has closed a licencing agreement with US-based Threshold Pharmaceuticals Inc. The cooperation centres around the hypoxia­-activated drug TH-302, which is currently being studied in a global Phase III study....

GermanyGermany

29.02.2012

Munich – Looking back with satisfaction and bent on a prize for good behaviour, German biopharmaceutical company Wilex AG reported yesterday on the fiscal year 2011 and outlined the shores in sight. The 2011 total revenue was...

GermanyGermany

17.02.2012

Brussels – European cartilage researchers intensify their cooperation. The 'gristle network' comprises scientists from Belgium, France, Germany and Luxembourg. Its members plan to meet regularly to exchange views and information...

27.01.2012

Thousand Oaks/Munich - Bling bling for blinatumomab. It is a compliment for the European life sciences scene and sad news at the same time. Amgen Inc., the world's largest biotechnology company, agreed to buy Micromet Inc., an...

GermanyGermany

20.01.2012

Martinsried - SHELTER is responsible for the fact that the stocks of 4SC behaved like a rodeo horse on Thursday. The shares rose in several stages up to 63%, only to settle at a mere 43% rise at the end of the day. SHELTER is a...

GermanyGermany

17.01.2012

Ludwigshafen – BASF Plant Science GmbH, the agrochemistry and biotech arm of the world-largest chemistry company, thinks that it has outstayed its welcome in Europe. Over the next two years, most of the green biotechnology...

GermanyGermany

10.01.2012

Munich - It is the accolade for Micromet. The German company, which is listed on the U.S. stock exchange, announced today that it has entered into a Cooperative Research and Development Agreement (CRADA) with the renowned US...

Displaying results 1 to 10 out of 454

1-10 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/news/messages-archive/archive-germany/article/ip-flash.html

Events

All Events

Stock list

All quotes

TOP

  • ADDEX3.51 CHF12.14%
  • STRATEC BIOMEDICAL41.09 EUR4.55%
  • MEDIGENE4.00 EUR2.30%

FLOP

  • CYTOS0.18 CHF-5.26%
  • MOLOGEN6.60 EUR-2.22%
  • SANTHERA86.95 CHF-1.92%

TOP

  • PAION3.22 EUR35.3%
  • CO.DON3.14 EUR28.2%
  • FORMYCON8.20 EUR16.6%

FLOP

  • CYTOS0.18 CHF-30.8%
  • EVOTEC3.10 EUR-15.8%
  • 4SC1.04 EUR-15.4%

TOP

  • SANTHERA86.95 CHF2112.5%
  • PAION3.22 EUR228.6%
  • CO.DON3.14 EUR223.7%

FLOP

  • CYTOS0.18 CHF-95.4%
  • 4SC1.04 EUR-45.0%
  • MOLOGEN6.60 EUR-44.0%

No liability assumed, Date: 30.09.2014


Current issue

All issues

Product of the week

Products